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Synthesis, Structural Determination, and Pharmacology of 
Putative Dinitroaniline Antimalarials 
Alessio del Casino,[a] Valentina Lukinović,[b] Rakesh Bhatt,[c] Laura E. Randle,[a]  Michael J. 
Dascombe,[d] Brian J. Fennell,⊥ [e] Michael G.B. Drew,[f] Angus Bell,# [e] Alistair J. Fielding,* [a] Fyaz M.D. 
Ismail*[a] 
Abstract: A series of novel, homologous compounds possessing the 
general formula N1-Nn-bis(2,6-dinitro-4-trifluormethylphenyl)-1,n-
diamino alkanes (where n = 4, 6, 10 or 12), were designed to probe 
inter- and intra- binding site dimensions in malarial parasite 
(Plasmodium) tubulin. Various crystal structures, including chloralin 
and trifluralin, an isopropyl dimer, and 2,6-dinitro-4-trifluoromethyl-
phenylamine, were determined. Dinitroanilines, when soluble, were 
evaluated both in culture and in vivo.  Trifluralin was up to 2-fold more 
active than chloralin against cultured parasites. The isopropyl dimer 
was water soluble (>5 mM) and revealed activity superior to that of 
chloralin in culture. The effects of selected dinitroanilines upon the 
mitotic microtubular structures of Plasmodium, the putative target of 
these dinitroanilines, were also determined. Electronic properties of 
the molecules were calculated using DFT (HF/6-31+G* level) to 
ascertain whether incorporation of such a pharmacophore could allow 
both QSAR and rational development of more selectively toxic 
antiparasitic agents. 
Introduction 
Malaria is a parasitic infection transmitted to humans (and 
other animals) by female Anopheles mosquitoes when taking a 
blood meal.[1]The increase in drug resistant forms of Plasmodium, 
especially of the P. falciparum species,[2] continues to threaten 
tropical and sub-tropical regions of the world and with climate 
change, infections could spread to other, currently malaria free 
zones. 
  The most recent guidelines for the treatment of 
uncomplicated malarial infections suggest various antimalarial 
combination therapies which include: artemether and 
lumefantrine, artesunate and (amodiaquine or mefloquine); 
dihydroartemsininin + piperaquine or a triple combination therapy 
of artesunate + sulfadoxine-pyrimethamine. [3] However, adverse 
side effects of certain antimalarial drugs in current use, [4] and the 
appearance and propagation of drug resistant strains of 
Plasmodium [2b] necessitate the discovery and development of 
new and less toxic chemotherapeutic agents with novel modes of 
action.[5]  
A wide variety of endogenous compounds and xenobiotics 
produce directly (or indirectly) reactive oxygen species (ROS) that 
can induce oxidative stress in both the infected host and parasite. 
Often ROS are generated by electron transfer (ET) or other routes 
mediated by free radicals. Principal ET functionalities are 
quinones (or their precursors), conjugated imines, metal 
complexes and aromatic nitro compounds (ArNO2). Certain 
dinitroaniline herbicides, [6] (Figure 1) and their analogues [7] which 
are photo-labile[8] also exhibit activity against Leishmaniasis, a 
disease endemic to tropical and sub-tropical regions, [6] both in 
culture and in vivo.[7, 9] These compounds have also exhibited 
activity against a range of parasites commonly infecting humans 
and domesticated animals, including Plasmodium,[10] 
Cryptosporidium, [11] Leishmania, [9a, 12] Entamoeba [13], Babesia[14] 
and Toxoplasma. [15] One such nitroaromatic compound, trifluralin 
1 (Figure 1), [16] a widely used commercial pre-emergent herbicide, 
was initially considered the active agent against leishmaniasis. [6] 
However, subsequent investigations implicated its industrial 
precursor, chloralin 5 as the true active molecule. [17] 5 was found 
to be a contaminate of commercial samples of trifluralin, 
confounding ascription of bioactivity within the dinitroaniline class 
of compounds. Since 5 is one hundred times more potent than 1 
against Leishmania promastigotes and targets parasite tubulin, [18] 
it has attracted significant attention from parasitologists. 
Reversible polymerisation of tubulin facilitates organelle transport, 
chromosome segregation, and maintains cell structure integrity. 
[10a, 19] Although, tubulins are well-conserved protein families, 
slight sequence differences between parasite and human tubulins 
can drastically affect the activity of certain microtubule inhibitors 
making them candidate drug targets.[18c, 20]  In the case of 
benzimidazole antihelmintics, [21] this differential toxicity has been 
exploited in chemotherapy. [22] The inhibitory activity of 5 has been 
associated with displacement of its reactive C-4 chloro moiety by 
cysteine residues present in Leishmania tubulin, thereby inhibiting 
microtubule assembly. [17a] 
  Dinitroanilines appear to inhibit distinct parts of the 
developmental cycles of protozoal parasites. For example  
oryzalin 3 irreversibly arrested trophozoite mitosis in E. histolytica. 
[13] In Toxoplasma gondii, dinitroanilines appear to block nuclear 
division by inhibition of intra-nuclear spindle formation, but other 
cytoskeletal components were also differentially affected by the 
drugs tested. [15] Isolation of oryzalin-resistant Toxoplasma gondii 
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clones shows that resistance can be induced by point mutations, 
in α-tubulin. [23] 
 
 
Figure 1. Chemical structures and numbering. Trifluralin 1, pendimethalin 2, 
oryzalin 3, desaminomethyloryzalin 4,  chloralin 5, 2-chloro-3, 5-
dinitrobenzotrifluoride (isochloralin) 6, 4-chloro-3-nitrobenzotrifluoride 7, 2,4-
dinitro-5-nitrobenzotrifiuoride 8, N1,N3-bis-(2,6-dinitro-4-trifluoromethyl-phenyl)-
propane-1,2-diamine, where n = 2, 9;  where n = 4, 10;  where n = 6, 11; where 
n = 10, 12; where n = 12, 13, 2,6-dinitro-4-trifluoromethyl-phenylamine 14, 
chloramphenicol 15; 2-2-nitro-1H-imidazol-1yl-N-(2,2,3,3,3-pentafluoropropyl)-
acetamide (EF5) 16, [(7-nitro-2,3-dioxo-1,2,3,4-tetrahydro-quinoxalin-5-
ylmethyl)-amino]-methyl)-phosphonic acid (AMP397) 17. 
Studies of the effects of dinitroaniline compounds against 
malarial parasites have shown that they are selectively toxic to 
parasite rather than host cells but lack the potency required for 
further development as antimalarial agents. [10a, 24] The study of 
Kaidoh et al.[24c] showed by electron microscopy that micromolar 
(µM concentrations of 1 caused fragmentation and increased 
diameter of microtubules and dissolution of the sub-pellicular 
microtubule complex in P. falciparum gametocytes. Fennell et 
al.[25] using asexual blood-staged parasites demonstrated that 1 
and 3 inhibited progression through schizogony, blocked mitotic 
division, and caused accumulation of abnormal microtubular 
structures. Moreover, radiolabelled 1 interacted with purified, 
recombinant parasite tubulins but to a much lesser extent with 
bovine tubulins.  3 was also an inhibitor of liver-stage 
schizogony.[26]  
Identification of parasite tubulin as a novel target in 
Leishmania [17a] suggested to us that low cost dinitroaniline 
herbicides, such as 1, merited further evaluation and 
development as potential antimalarial agents. This study 
consisted of the syntheses, purification and quantum mechanical 
study and pharmacological evaluation of selected dinitroaniline 
analogues against Plasmodium in culture and in vivo. The 
presence of fluorine in these compounds imparts desirable 
pharmacological properties and delays premature metabolism. [27] 
Since both structural and electronic features dictate 
pharmacodynamic (drug-receptor interactions), this information 
was sought through X-ray diffraction of selected dinitroanilines. 
We also report the preparation and activity of a novel trifluralin 
dimer active against P. falciparum in culture.  
Results and Discussion 
Synthetic studies and compound selection procedure 
Several compounds were chosen from our drug bank for 
initial, concurrent evaluation against a lethal strain of P. berghei 
in mice and chloroquine-sensitive and -resistant strains of P. 
falciparum in culture. Selected substances were not compromised 
by poor physical properties [28] in order to facilitate testing in 
culture. Experiments in vivo were not restricted by aqueous 
solubility, because the subcutaneous (s.c.) route was used for 
injections formulated in dimethyl sulfoxide (DMSO) and olive oil.  
Mindful that the industrial precursor of 1 has been proposed 
to be the active antiparasitic agent, we included in this study an 
isomer of 5, isochloralin 6 and the structurally related 8. We 
hypothesised that evaluation of the antimalarial activity of this 
potentially iso-lipophilic isomer of 5 would indicate if steric 
congestion, around the labile halide group, depresses the 
previously postulated attack by thiols presumed present within the 
target receptor. Structure-activity relationship analyses of 5 
implicate the displaceable chloride moiety activated by a single 
nitro group as the pharmacophore; these contributed to selecting 
compound 7 for antimalarial tests. Hence, a judicious selection 
and evaluation of compounds depicted in Figure 1 could reveal a 
functional antimalarial pharmacophore for dinitroanilines. 
The initial aim was to estimate the average inter- or intra- 
binding site dimensions in tubulin polymers using a homologation 
strategy. Consequently, a series of dimers (compounds 9 - 13, 
Figure 1) were designed for preliminary evaluation in culture. 
Compounds 1 and 2 (Figure 1) were synthesised using a 
commercial robot (Anachem SK233) capable of automated 
synthesis coupled to a HPLC-MS system, [29] which screened a 
wide variety of bases and solvents (data not shown) to establish 
optimal reaction conditions and reagents that effectively promoted 
SNAr reactions between a variety of amines and various mono-, 
di- and tri-nitro substituted haloarenes.  Inclusion of an organic 
weak base, triethylamine to scavenge HCl generated during the 
SNAr reaction, and toluene at reflux as solvent, under a protective 
blanket of argon, proved superior to other base/solvent conditions 
examined. High boiling solvents were especially problematic as 
dinitroanilines tend to readily sublime under moderate vacuum. A 
transient red colouration noted during drop-wise addition of 
reagents during reactions suggested participation of the nitro 
group in stabilising the labile Meisenheimer intermediate complex 
formed during the dechloro-amination reaction.[30]  
The construction of 9 proved interesting since refluxing 5 
with 1,3-diaminpropane provided a compound that proved 
insoluble in choroform so a comparative NMR spectrum could not 
be obtained. The NMR spectrum in DMSO was unsymmetrical 
suggesting that the product was not the postulated compound. A 
crystal suitable for a diffraction study revealed that a rare 
rearrangement to the isopropyl dimer, a situation described in the 
literature during the base catalysed preparation of (2-
diethylamino-propyl)-carbamic acid (2-methyl-cyclohexylester) 
from N,N-diethyl-propane-1,3-diamine. [31]  
X-ray Crystallography 
The structures of 1, 5, 8, 9 and 14 are given in Figure 2 and 
structural details have been deposited with the Cambridge 
Crystallographic Data Centre (reference numbers CCDC 219352 
- 219356). Crystal data and refinement details are shown in Table 
S1. In the structure of 1, the nitrogen atom has a trigonal 
environment with the three subtended angles at nitrogen adding 
up to 359.6(2)o. The plane of C(4), N(7), C(71), C(81) intersects 
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that of the phenyl ring at an angle of 36.4(2)o. The torsion angles 
of the ethyl groups are somewhat surprising being C4-N7-C71-
C72 126.1(4), N7-C71-C72-C73 -63.2(7) and C4-N7-C81-C82 
118.9(5), N7-C81-C82-C83 -172.3(4)o. Hence, one propyl group 
is in a -gauche conformation and the other is in the expected trans 
environment. The two nitro groups make angles of 47.5(2) and 
54.6(2)o with the phenyl ring. 
Clearly, the rotation of the two-alkyl groups out of the plane 
is a steric effect concomitant with an opposite rotation from the 
nitro groups. Thus, with reference to Figure 2, O(32) is below the 
plane while C(71) is above and O(52) is above the plane while 
C(81) is below. The O...C distances in the two cases are 2.869(6) 
and 2.942(5) Å. 
  In the structure of chloralin 5 the two molecules in the 
asymmetric unit show different types of disorder. Molecule A 
contains rotational disorder of the -CF3 group, whereas molecule 
B contains rotational disorder of one nitro group with the oxygen 
atoms alternatively above and below the ring plane as well as 
rotational disorder of the -CF3 group. In A, the two nitro groups 
intersect the ring plane at angles of 61.6(3), 34.9(5)o and in B 
63.0(3) and 53.9(3) or 56.9(10)o. So it is clear that the presence 
of the chloride substituent intermediate between the two nitro 
group has had a similar effect on the orientation of the nitro groups 
to the -N(propyl)2  group in 1.   
In the structure of 8 the nitro group is twisted out of the plane 
of the aromatic ring by an angle of 38.3(2)o. This is despite the 
fact that there is a substituent only on one side of the nitrate. In 
this structure the -CF3 group is ordered unlike the situation in 1 
and 5, presumably this is due to the presence of the adjacent Cl(6) 
atom. It is noteworthy that the -CF3 group takes up a conformation 
in which two of the fluorine atoms are almost equidistant from the 
adjacent Cl(6) atom at 3.114(3), 3.128(4) Å. 
The structure of the trifluralin dimer N1,N2-di-(2,6~dinitro-4-
trifluoromethy1phenyl)-l,,3-propylenediamine 9 was obtained as a 
racemic crystal and is somewhat surprising because the two 
amine nitrogen atoms are only 2.908(9) Å apart because the 
linkage between them contains several torsion angles that are 
gauche rather than trans as might be expected;
 
Figure 2. The structures of 1, 5, 8, 9 and 14 with ellipsoids at 25 % probability, and intramolecular hydrogen bonds are shown as dotted lines. 1 has one 
propyl group in a -gauche and the other in a -trans conformation. The –CF3 group is disordered over two orientations, only the major component is shown. 
Molecule A is shown for 5 with one set of positions for the disordered -CF3 group. Molecule B has a similar basic geometry but rotational disorder in 
one nitrate and a -CF3 group. The conformation of the -CF3 group in 8 ensures that fluorine atoms are staggered with respect to the adjacent Cl(6). 9 
has N…N distances of 2.642(5) and 2.639(5) Å.  
 
 
 
being for C(5)-C(4)-N(41)-C(42) -152.3(4)o, C(4)-N(41)-C(42)-
C(43) 136.7(4)o, N(41)-C(42)-C(43)-N(44) 65.4(4)o, C(42)-C(43)-
N(44)-C(51) -103.8(5)o, C(43)-N(44)-C(51)-C(56) 159.3(4)o. The 
two amine nitrogen atoms N(41) and N(44) both form 
intramolecular hydrogen bonds with their adjacent oxygen atom 
O(72), O(52), respectively, with dimensions N…O, N-H…O and 
H…O 2.642(5) Å, 130.6o, 2.00 Å and 2.639(5) Å, 127.6o, 2.02 Å 
respectively Å). These two nitro groups intersect the plane of the 
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benzene ring at angles of 9.5(11), 7.9(7)o, respectively, while the 
other nitro groups which are sterically hindered by the carbon 
atoms C(1) and C(3) are twisted by angles of 40.2(6), 53.8(5)o out 
of the plane of the benzene rings. The two aromatic rings intersect 
at an angle of 60.7(2)o though there are no intramolecular 
hydrogen bonds between them, nor indeed any close contacts 
between the two aromatic rings and their substituents.  
As further confirmation of the correlation between the 
rotation of the nitro group relative to the phenyl ring and the 
substituent(s) on the amine nitrogen, the structure of 2,6-dinitro-
4-trifluoromethyl-phenylamine 14 was also determined.  
Here, the two-nitro groups are adjacent to an amine group 
and formed hydrogen bonds via O32 and O52. Dimensions were 
O…H 2.01, 2.01 Å, O…H-N 128, 130o  and O…N  2.630(9), 
2.642(9) Å, respectively. As a consequence  the angles of rotation 
of the two groups relative to the ring were 9.8(12) and 8.6(10)º 
thus showing that steric effects are paramount in considering the 
angle of rotation of the nitro groups in the molecules reported 
here. 
 
Theoretical calculations 
Quantum mechanics calculations using the Gaussian03 
program [32] were carried out to establish whether packing effects 
had any serious effects on the molecular geometry of these 
complexes. Calculations on trifluralin 1 using the crystal structure 
as an input model, converged at the B3LYP/6-31+G* level with 
the N(7) having a trigonal environment. The angle between the 
plane of C(4), N(7), C(71), C(81) and the phenyl ring was 38.6º 
while the nitro groups intersected the phenyl ring at values of 42.1, 
42.0º  confirming that the conformation found in the crystal 
structure is not affected significantly by crystal packing, although 
it might be expected that both N-propyl groups would have the 
trans conformation though this would not feasible due to clashes 
between the chains. 
Equivalent calculations have been carried out on this 
molecule with the NPr2 groups replaced with (a) NH2 and (b) 
NHMe. In molecule (a), the calculation resulted in a planar 
conformation in which both nitro groups and the NH2 group were 
coplanar with the phenyl ring, angles of intersection 0.4o 
presumably forming some weak interaction between the amine 
hydrogen atoms and the nitro groups. This can be compared to 
the crystal structure of 14 where the nitro groups are slightly 
twisted out of the plane of the phenyl ring by angles of 9.8(12), 
8.6(10)o. In the case of molecule (b), the nitro group adjacent to 
the N-H group remained closely planar with the phenyl ring 
making an intersection of 8.1º while the nitro group adjacent to the 
methyl group twisted by 49.8º. This result can be compared to that 
found in the crystal structure of the trifluralin dimer 9 where there 
are two independent –NHR groups and the angles found are 
9.5(11), 7.9(7) for the nitro group adjacent to –NH and 40.2(6), 
53.8(5)o for the nitro group adjacent to –NR. 
These experimental and theoretical results show that the 
bulk of the NPr2 group in 1 has a similar effect to that of the 
chlorine in chloralin 5 on the twist in the adjacent nitro groups. 
However, with a primary amine, both adjacent nitro groups will be 
coplanar with the nitro group while only one nitro group in a 
secondary amine is twisted significantly from the plane. This 
difference in structure of the adjacent nitro groups may indicate 
that only the tertiary amine will be active and that the presence of 
a hydrogen atom bonded to the nitrogen and forming a weak 
hydrogen bond to the adjacent nitro group may affect activity.  
We next investigated the electronic properties of molecules 
5, 6, 7 and 8 (Figure 1) to establish whether there were any 
obvious correlations with activity, the first two being active and 
latter two inactive. Selected parameters are shown in Table 1. 
Clearly all but the charge on the chlorine can be correlated with 
biological activity but with only four test compounds, no decisive 
conclusions can be drawn here but may be helpful in drawing 
conclusions as to which substituents enhance electron transfer in 
future studies (see EPR section). 
 
Table 1. Selected physiochemical and electronic properties of compounds 
tested in culture and in vivo. 
 
 charge 
on Cl 
HOMO(a.u.) LUMO(a.u.) C-Cl(Å) µ(D) 
5 0.361 -0.319 0.136 1.720 1.601 
6 0.430 -0.323 -0.147 1.722 1.826 
7 0.360 -0.310 0.136 1.760 4.301 
8 0.357, 
0.327 
-0.302 0.126    1.741,       
1.735  
2.978 
 
Pharmacological evaluations 
Six potential antimalarials were evaluated against the 
cloned P. falciparum subline FCH5.C2 [33] and the chloroquine- 
and pyrimethamine-resistant strain K1/Thailand (Table 2), and in 
vivo against lethal P. berghei (Table 3), previously utilised to 
construct our functional in vivo receptor for bisquinolines. [34] Both 
evaluations used commercially (Sigma-Aldrich) available 
chloroquine diphosphate  and artemisinin as standard antimalarial 
drugs.  
 
Table 2. Antimalarial activity of dinitroanilines against two cultured strains of P. 
falciparum. 
Compound IC50 FCH5.C2 IC50 K1/Thailand 
 48 h 72 h 48 h 72 h 
 [µM] [µM] [µM] [µM] 
1     5.9[a]     2.7[c]       6.5[c]     3.2[c] 
5 7.1 5.9 10.0 6.4 
6 7.3 7.8     11.0[a] 5.5 
7 >64[c] >64[c] >64[c] >64[c] 
8 >64[c] >64[c] >64[c] >64[c] 
9 4.8[b] 4.9  3.8[c] 3.8[a] 
[a] Different from chloralin at p<0.05, Student’s t-test. [b] Different from chloralin 
at p<0.01, Student’s t-test. [c] Different from chloralin at p<0.001, Student’s t-
test. 
 
Table 3. Antimalarial activity of dinitroaniline compounds against P. berghei N 
in mice. 
Compound Dose/ µmol 
kg-1 
P. berghei parasitaemia % 
control 
1 75 89 ± 11 
 149 84 ± 16 
 298 87 ± 10 
 597 87 ± 8 
5 46 T 71 ± 14 
 92 T 79 ±  7 
 185 T 49 ± 9[b] 
6 46 T 66 (54 – 78) [a] 
 92 T 86 ± 8 
7 228 98 ± 10 
 443 85 ± 16 
8 96 78 ± 11 
 192 98 ± 4 
 385 95 ± 13 
Compounds were injected s.c. twice daily (total number of doses = 5) in mice 
(initial group sizes 5-10) inoculated with P. berghei N. Parasitaemias were 
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determined 72 hr after inoculation and expressed as percentages (mean ± SEM 
for 4 – 7 animals on day 3, except [a] average and range for 2 mice) of control 
values in concurrent vehicle-treated (control) malarial mice. [b]  P < 0.05; T 
denotes toxicity (hypothermia, weight loss, reduced motor activity) associated 
with therapy. 
 
Antimalarial activity in vivo 
Results show that 1 was not antimalarial in the in vivo three 
day-suppression test, against P. berghei N in mice, used in this 
study with doses in the range 25 - 200 mg kg-1 (75 – 597 µmol kg-
1) s.c. twice daily (Table 3). All animals in this study survived 
treatment with 1. In contrast, 5 was found to be toxic; a single 
injection of chloralin 200 mg (739 µmol) or 100 mg (370 µmol) kg-
1 s.c. caused death or necessitated humane killing, therefore, 
doses of 12.5, 25 and 50 mg (46, 92 and 185 µmol respectively) 
kg-1 s.c. twice daily were used in the three day malaria 
suppression test. Antimalarial activity was evident with 5 at 25 (92 
µmol; P < 0.1) and 50 mg (185 µmol; P < 0.05) kg-1 s.c.; ID50 50 
mg (185 µmol) kg-1), but toxicity was evident as hypothermia, 
weight loss and decreased motor activity in some animals. A 
readily available, theoretically isolipophilic isomer of 5, 2-chloro-3, 
5-dinitrobenzotrifluoride 6, was also toxic following a single 
injection s.c. of 100 mg (370 µmol) kg-1. Reduced doses of 25 mg 
(92 µmol) and 12.5 mg (46 µmol) kg-1 twice daily also caused toxic 
effects similar to 5 in mice used in the antimalarial screen. 
Although, 6 at 12.5 mg (46 µmol) kg-1 reduced P. berghei 
parasitaemia to 66 % of that seen in vehicle-treated mice, the low 
number of survivors on day 3 (2 from initial group of five mice) 
makes this result statistically insignificant). Compounds 4-chloro-
3-nitrobenzotrifluoride 7 (50 and 100 mg kg-1; 228 and 443 µmol 
kg-1, respectively) and 2,4-dichloro-5-nitrobenzotrifluoride 8 (25, 
50 and 100 mg kg-1; 96, 192 and 385 µmol kg-1, respectively) were 
neither antimalarial (Table 1) nor toxic in mice during the period 
of the three day suppression test.  
It is relevant to note that 1 is also inactive in vivo against 
Cryptosporidium parvum (dosed at 100 mg kg-1)[11] and is neither 
carcinogenic or tumorigenic of in male B6C3F1 mice or in 
Osborne-Mendel rats of either sex.[35] 1 is rapidly cleared in rats 
by faecal and urinary excretion with only 10 % remaining 
unmetabolised.[36] Rapid metabolism and clearance in rodents[37] 
may account for the inactivity of 1 in rodent models of Plasmodium 
and Cryptosporidium in vivo. Another possibility is that the high 
log P value of 1 (4.81) constrains this substance at or around the 
site of injection. [11] 
We were unable to separate the antimalarial effects of 5 or 
its analogue, 6 from their toxicity in mice. The compounds 4-
chloro-3-nitrobenzotrifluoride 7 and 2,4-dinitro-5-nitro-
benzotrifluoride 8 had no antimalarial activity or toxicity and thus 
appear to lack the pharmacophore associated with 5 and 6. 
 
Antimalarial activity in culture 
         Compounds 9 – 13 were not fully soluble in DMSO at 
suitable concentrations (>5 mM), limiting acquisition of a more 
complete QSAR profile. Although, 5 may well be the active toxic 
and antileishmanial component of 1 in other investigations [17a], it 
was not a contaminant in our rigorously purified samples.  
Antimalarial activity was evaluated after 48 and 72 h 
incubations using asynchronous cultures of chloroquine-sensitive 
and -resistant strains of P. falciparum (Table 2). 1 was slightly but 
significantly more active than 5 against both strains. The observed 
activity of 1 is consistent with previously published data. [24-26, 38] 
The potency of the compound was unaffected by the resistances 
of the K1/Thailand strain to unrelated agents. The theoretically 
isolipophilic isomer of 5, 6, displayed similar activity to 5. Activity 
was abolished by the removal of one of the nitro- groups of 5, 7, 
and was not restored by the extra Cl in 8. The trifluralin dimer 9 
was slightly more active than 1 so is possible that only one half of 
this dimer interacts at the receptor site, particularly as the 
relatively folded conformation makes it unlikely that both aromatic 
rings can simultaneously interact at a putative target site. 
However, interestingly, the activity of 9 was either superior or 
equal to the monomeric 5 and 6. Disappointingly, other members 
of the homologous series proved insoluble at the levels required 
for testing on cultured parasites. When strategies for improving 
the solubility of these putative antimalarials are discovered, it will 
be interesting to see whether a dimer can be found that is superior 
to 1 as a result of an optimised linker length. 
Examination of mitotic microtubular structures of 1- or 5-
treated parasites by immunofluorescence revealed a breakdown 
of the normal hemispindles and microtubule-organising centres 
and their replacement by fragmented tubulin labelling (Figure 3). 
 
 
 
Figure 3.  Mitotic microtubular structures of cultured P. falciparum 
parasites viewed by immunofluorescence using antibodies to P. falciparum 
β-tubulin (left) and DAPI  nuclear stain (right).  (a) Untreated parasites: 
note microtubule-organizing centres (small arrow) and hemispindles (large 
arrow) and distinct nuclear bodies (right).  (b) treated with 1; (c) treated 
with 5.  Note in both (b) and (c) tubulin fluorescence in small dots with 
slight, diffuse background and loss of normal microtubular structures 
(arrowheads), and disorganisation of nuclear DNA (right).  Exposure to 
inhibitors was 20 µM for 6 h.  
 
This may be the result of net depolymerisation of these 
microtubules, but it is not clear why the same diffuse labelling 
seen with vinblastine, dolastatin and auristatin PE [39] is not 
apparent. This effect is likely to be more relevant to growth 
inhibition than the previously reported effects on invasion and the 
f-MAST [38] because of the lower concentrations used in the 
present study. 
Dow et al. [10b] reported the activities of 1, 5, pendimethalin, 
benfluralin and 3 against P. berghei in culture and in a rat model 
of malaria. They reported that while moderately active against 
cultured parasites (IC50, 1.3 µM), 1 did not reach sufficient plasma 
levels in rats to obtain an antimalarial effect in vivo. Their results 
differ slightly from ours in the lower activity of 5 against cultured 
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parasites (IC50, 16 µM) but this could be a species difference. 5 
was not tested in vivo by these investigators.  
 
Mechanism of antimalarial action 
Support for an ipso-de-chloro-thiolation mechanism 
(compare to the aforementioned synthesis of 9, where the amine 
is replaced by a cysteine residue) is provided by evidence that 5 
interferes with Leishmania tubulin[19] and microtubule assembly in 
culture (IC50 = 22 µM), whereas 1, which possesses the much 
poorer amino-bis-propyl leaving group, does not. [40] The 
mechanism of inhibition of thiol dependent enzymes has been 
reviewed. [41] However, the proposed mechanism of antitubulin 
action involving certain mono-nitroanilines has been questioned. 
[18a] Analogues tested against purified tubulin failed to inhibit 
microtubule assembly, but had antileishmanial activity in culture, 
which suggests that further analogue development may reveal 
non-toxic agents. 1 may bind to its receptor by non-covalent 
electrostatic and van der Waals interactions, whereas 5 can form 
a covalent adduct with nucleophilic side chains of parasite protein 
amino acids. Computational modelling has suggested binding 
sites within both dinitroanilines in kinetoplastid and apicomplexan 
α-tubulin. However, there are four amino acid differences 
between the kinetoplastid and apicomplexan binding site residues, 
which might contribute to the differential efficacy of specific 
dinitroanilines.[42] 
Although, one electron reduction of the nitro group is the 
basis of the antiparasitic action of nitroimidazole drugs, [43] this 
does not appear to be the mode of action in intact cells. [44] For 
instance, 5-nitrofurfural N-butyl semicarbazone [45] has been 
shown to have antitrypanosomal activities, targeting 
trypanothione reductase through a nitro anion radical mechanism. 
Nitric oxide donors have been reported to inhibit Leishmania 
cyteine proteinase [46] and a similar mode of action could apply to 
Plasmodium. Although, nitrofurantoin radical anion and GSH 
cannot be detected under physiological conditions within 
parasites, [43a] such experiments need to be performed for 
dinitroanilines against both drug-resistant and -sensitive 
Plasmodium.  
 
EPR Studies of trifularlin-heme interactions  
Previous investigations have indicated that 3 has an effect 
on the liver stage of the Plasmodium life cycle.[26] As this organ is 
a major site of drug deactivation and occasionally inactivation 
during xenobiotic metabolism especially with heme containing 
enzymes such as cytochrome P450’s, the interaction of reduced 
1 with heme was of interest. In order to elucidate the interaction 
of 1 with hemin, continuous-wave (CW) electron paramagnetic 
resonance (EPR) spectra (Figure 4) were recorded in order to 
investigate the spin state of the heme iron. The spectrum of hemin 
is typical of high spin ferric heme (S = 5/2) with turning points at 
g⊥ eff = 6.0 and g‖ eff = 1.99. Upon addition of 4-fold molar excess 
of 1 under aerobic conditions a dramatic decrease in the intensity 
of the ferric resonance was seen with no subsequent new signals 
as has previously been observed with compounds related to 
metaquine.[47] These observations suggest a change of iron spin 
state to an EPR silent state. The mechanism of action will need 
further investigation. 
 
Figure 4. EPR spectra of hemin and hemin mixed with trifluralin 1. 9 GHz CW 
EPR spectra of a solution of 200 µM hemin (black), hemin on manual 5 sec 
mixing of 4-fold molar excess of 1 (green). Hemin concentration was 200 µM in 
all experiments. Inset shows magnification of the g⊥eff region. Spectra were 
recorded at 5 K, 100 kHz, 0.4 mT modulation amplitude, 1 mW, 1 scan. 
 
Mechanism of toxicity 
The presence of halogen in natural products, previously 
considered a rare occurrence, has been identified in over 2600 
compounds. [48] Non-toxic, low molecular weight drugs containing 
both nitro and trifluoromethyl groups have been successfully 
designed including EF5 16 [49] and antiepileptic AMP397 17, [50] 
although possessing a “structural alert” (the nitro group), [51] 
sufficient safety data have initiated clinical development. [52] 
Similar effects on mammalian tubulin have been described with 
small aromatic electrophiles such as 1-fluoro-2, 4-dinitrobenzene 
and 2,4-dichlorobenzyl thiocyanate [53] suggesting that the 
antimalarial activity may involve, in part, formation of a covalent 
adduct within parasite tubulin [54] but may also result in toxicity to 
the host. 
The mechanism of action of several clinically useful drugs 
including vasodilators such as nitro-glycerine, radiosensitisers 
such as etanidazole (SR2508), which targets brainstem glioma, 
[55] and antibiotics such as metronidazole, [56] certain 
antileishmanials [57] and putative anticancer agents [44] require the 
presence of a nitro group. Chloramphenicol 15, a halogenated 
nitrobenzene antibiotic produced by Streptomyces venezuelae [48] 
and found in the moon snail Lunatia heros, [58] lacks systemic 
toxicity following topical application that prevents opportunistic 
infections following eye surgery [59]. However, it has been noted 
that compounds containing a nitro group are over-represented in 
the Ames test whether the compounds are metabolically activated 
or not. [51b] In the case of 5 the results of this study indicate toxicity 
may preclude further development of this compound. [60] 5 was 
found in this study to be antimalarial both in culture and in vivo, 
but its antimalarial activity was associated with host toxicity. This 
toxicity indicates a lack of selectivity by 5 for Plasmodium and 
suggests the compound is not preferentially sequestered by the 
parasite to an adequate degree for antimalarial drug use. 1 
displayed antimalarial activity in culture, but not in vivo in mice. 1 
also failed to display significant toxicity in this study. As indicated 
above, Dow et al. [10b] reported a similar profile; 1 inhibited P. 
berghei in culture but not in vivo in rats following oral 
administration. These researchers suggested 1 was inactive in 
vivo because plasma concentrations attained after oral dosing 
were inadequate for antimalarial activity, perhaps due to the high 
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solubility of 1 in host body fat, [10b] or reduction by a first pass effect 
in the liver. Measurements of the uptake of radiolabelled 1 into P. 
falciparum suggested that accumulation in membranes may also 
limit the activity of 1 in cultured parasites.[61] However, since the 
trifluralin class of compounds undergo extensive metabolism, at 
least within the rat,[62] secondary xenobiotic metabolites could 
also be responsible for antiparasitic activity.[26] Since 
dinitrophenols, putative metabolites of chloralin type compounds, 
have significant toxicity, development of this class of compound 
will require extensive pre-clinical toxicity screening. 
Conclusions 
The long-term aims of our research on dinitroanilines as 
potential antiparasitic drugs are to: i) reduce the toxicity of the 
nitro moieties; ii) decrease the possibility of idiosyncratic drug 
reactions by structural modification; [63] iii) ensure selective uptake 
into parasites; iv) measure intra and inter-subunit tubulin binding 
site dimensions and v) identify the trifluralin pharmacophore. 
These aims require compounds with improved physical properties 
compared to trifluralin and the novel dimers reported here. 
5 can be considered a target for further development, 
because it is active against Plasmodium, however, it does display 
toxicity in the host. The discrepancy between the antimalarial 
activities of 1 in culture and in vivo cannot be readily explained. 
Low bioavailability due to uptake into host body fat and/or rapid 
metabolism and excretion may explain the lack of activity in 
laboratory rodents in vivo. The number of compounds examined 
so far is insufficient for establishing robust QSAR. In addition, 
compounds with better drug formulation profiles could be 
generated by molecular modifications that enhance aqueous 
solubility. Unlike in Leishmania, 1 [and also 9] was found in this 
study to have activity against parasites in culture that could not be 
ascribed to contaminants in the test substances. Identification of 
a compound of similar potency to 1 against drug-resistant and -
sensitive strains of Plasmodium in culture 9 indicates that the 
presence of the halide is not an absolute requirement for 
antimalarial activity. This observation suggests the nitro group 
may be undergoing bioactivation and may act by production of 
ROS as evidenced by interaction with reduction of Fe(III) within 
heme.[46] 
Both QSAR studies[64] and drugs co-crystallised with 
putative target receptors have enabled rational drug evolution 
towards more selectively toxic antiparasitic agents. [52, 65] A 
computational docking study of 3, 1 and 5 to tubulin, found in 
Toxopoplasma gondii, suggests that in this parasite, they exert 
their action by disrupting M-N loop contacts. [23] Studies have 
shown that antimitotic herbicides can bind to an unidentified site 
on malarial parasite tubulin and, notably, block development of 
liver-stage Plasmodium parasites.[26] Consequently, emphasis 
must now shift to understanding which of these are responsible 
for activity and must in turn serve as further lead compounds in 
the developing the next cycle in eventually developing clinically 
useful drugs. 
Further studies are needed to develop selective 
accumulation of such compounds into parasites whilst sparing 
host mitochondrial apparatus; the original concept of selective 
toxicity as promoted by A. Albert [66] has indicated that it is not that 
a compound is not toxic but it should be selectively toxic. If we 
develop compounds known to selectively accumulate in 
mitochondria, incorporation of dinitroaniline groups into 
frameworks[67]  may provide more effective compounds. In 
conclusion, until the target site of dinitroanilines in Plasmodium 
has been characterised, and details of the receptor site clarified, 
it will be difficult to identify selectively toxic compounds of this 
structural class that have the high safety margins required for 
clinical use.  
Supporting Information Summary 
Full experimental details and spectroscopic characterizations are 
given in the supporting information. 
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A series of novel dinitroaniline 
compounds were designed to probe 
inter- and intra- binding site 
dimensions in malarial parasite 
(Plasmodium) tubulin.  Various crystal 
structures, including chloralin and 
trifluralin, an isopropyl dimer, and 2,6-
dinitro-4-trifluoromethyl-phenylamine, 
were determined. Dinitroanilines, 
when soluble, were evaluated both in 
culture and in vivo. A new dimeric 
homologue of trifluralin showed 
antimalarial activity in vitro. Rational 
development of more selectively toxic 
antiparasitic agents is discussed. 
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